| $255M | ||
| $48M | ||
| $38M | ||
| $37M | ||
| $34M | ||
| $34M |
Buys | $0 | 0 | 0 |
Sells | $1,280,173 | 16 | 100 |
| Akinsanya Karen | See Remarks | 0 | $0 | 1 | $17,626 | $-17,626 |
| Tran Yvonne | EVP, CLO & CPO | 0 | $0 | 2 | $24,813 | $-24,813 |
| Herman Jenny | CAO | 0 | $0 | 3 | $28,134 | $-28,134 |
| Lorton Kenneth Patrick | EVP, CTO & COO, Software | 0 | $0 | 2 | $28,465 | $-28,465 |
| Abel Robert Lorne | See Remarks | 0 | $0 | 2 | $33,270 | $-33,270 |
| Jain Rachit | EVP & CFO | 0 | $0 | 3 | $45,439 | $-45,439 |
| Farid Ramy | President & CEO | 0 | $0 | 3 | $1.1M | $-1.1M |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and …
Over the last 12 months, insiders at Schrödinger, Inc. have bought $0 and sold $1.28M worth of Schrödinger, Inc. stock.
On average, over the past 5 years, insiders at Schrödinger, Inc. have bought $0 and sold $1.54M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,115 shares for transaction amount of $111,386 was made by Lebowitz Joel (EVP & CFO) on 2021‑02‑05.
| 2026-07-16 | Sale | Jain Rachit | EVP & CFO | 875 0.0012% | $15.60 | $13,647 | +33.01% | |
| 2026-04-17 | Sale | Farid Ramy | President & CEO | 43,000 0.059% | $12.21 | $524,944 | +33.63% | |
| 2026-04-16 | Sale | Farid Ramy | President & CEO | 43,000 0.0596% | $12.33 | $530,233 | +36.73% | |
| 2026-04-16 | Sale | Jain Rachit | EVP & CFO | 844 0.0012% | $12.75 | $10,758 | +36.73% | |
| 2026-03-06 | Sale | Herman Jenny | CAO | 608 0.0008% | $12.84 | $7,808 | +21.90% | |
| 2026-03-05 | Sale | Farid Ramy | President & CEO | 3,661 0.0049% | $12.91 | $47,249 | +18.50% | |
| 2026-03-05 | Sale | Lorton Kenneth Patrick | EVP, CTO & COO, Software | 1,222 0.0016% | $12.90 | $15,761 | +18.50% | |
| 2026-03-05 | Sale | Akinsanya Karen | See Remarks | 1,366 0.0018% | $12.90 | $17,626 | +18.50% | |
| 2026-03-05 | Sale | Tran Yvonne | EVP, CLO & CPO | 1,094 0.0015% | $12.89 | $14,107 | +18.50% | |
| 2026-03-05 | Sale | Jain Rachit | EVP & CFO | 1,631 0.0022% | $12.90 | $21,033 | +18.50% | |
| 2026-03-05 | Sale | Herman Jenny | CAO | 775 0.001% | $12.85 | $9,956 | +18.50% | |
| 2026-03-04 | Sale | Abel Robert Lorne | See Remarks | 1,300 0.0017% | $12.81 | $16,653 | +17.00% | |
| 2026-02-10 | Sale | Lorton Kenneth Patrick | EVP, CTO & COO, Software | 925 0.0013% | $13.73 | $12,704 | +11.30% | |
| 2026-02-10 | Sale | Herman Jenny | CAO | 752 0.001% | $13.79 | $10,370 | +11.30% | |
| 2026-02-10 | Sale | Tran Yvonne | EVP, CLO & CPO | 776 0.0011% | $13.80 | $10,705 | +11.30% | |
| 2026-02-09 | Sale | Abel Robert Lorne | See Remarks | 1,230 0.0017% | $13.51 | $16,617 | +11.32% | |
| 2025-10-16 | Sale | Dugan Margaret | Chief Medical Officer | 1,395 0.002% | $21.07 | $29,387 | -19.30% | |
| 2025-04-14 | Sale | Akinsanya Karen | President of R&D, Therapeutics | 16,723 0.0315% | $25.09 | $419,570 | -27.26% | |
| 2025-03-06 | Sale | Herman Jenny | SVP & Controller | 666 0.0009% | $21.11 | $14,059 | -6.41% | |
| 2025-03-03 | Sale | Porges Geoffrey Craig | EVP & CFO | 5,491 0.0077% | $21.76 | $119,484 | -6.97% |
| BILL & MELINDA GATES FOUNDATION TRUST | 10 percent owner | 6981664 9.3331% | $189.76M | 1 | 3 | +110.06% |
| Flynn James E | 10 percent owner | 250000 0.3342% | $6.79M | 1 | 0 | +110.06% |
| Lebowitz Joel | EVP & CFO | 0 0% | $0 | 1 | 13 | <0.0001% |
| Increased Positions | 103 | +39.31% | 5M | +7.69% |
| Decreased Positions | 112 | -42.75% | 5M | -7.57% |
| New Positions | 27 | New | 1M | New |
| Sold Out Positions | 33 | Sold Out | 521,900 | Sold Out |
| Total Postitions | 253 | -3.44% | 70M | +0.12% |
| Blackrock, Inc. | $171,909.00 | 14.71% | 9.56M | -215,974 | -2.21% | 2025-09-30 |
| Gates Foundation Trust | $125,530.00 | 10.74% | 6.98M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $113,977.00 | 9.75% | 6.34M | -277,572 | -4.2% | 2025-09-30 |
| Rubric Capital Management Lp | $94,733.00 | 8.11% | 5.27M | +268,817 | +5.38% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $81,891.00 | 7.01% | 4.55M | +904,619 | +24.78% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $59,400.00 | 5.08% | 3.3M | -111,621 | -3.27% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $47,448.00 | 4.06% | 2.64M | +47,443 | +1.83% | 2025-09-30 |
| Lazard Asset Management Llc | $42,189.00 | 3.61% | 2.35M | +927,234 | +65.33% | 2025-09-30 |
| State Street Corp | $39,647.00 | 3.39% | 2.21M | +19,278 | +0.88% | 2025-09-30 |
| Stephens Investment Management Group Llc | $39,431.00 | 3.37% | 2.19M | -68,300 | -3.02% | 2025-09-30 |